SCHEMBL23424751

SCHEMBL23424751

CC(C)c1ccccc1N1Cc2ccccc2C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
PKM P14618 3/20 0.53
KMT2A Q03164 3/20 0.50
TP53 P04637 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
PGR P06401 1/20 0.50
CYP3A4 P08684 1/20 0.50
GAA P10253 1/20 0.50
NFKB1 P19838 1/20 0.50
DRD1 P21728 1/20 0.50
HTT P42858 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
FAAH O00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9363533 0.85 NPC1 (0.49) NPC1RAB9APKMKMT2ATP53
SCHEMBL29628844 0.84 NPC1 (0.54) NPC1RAB9APKMKMT2ATP53
SCHEMBL11216784 0.84 NPC1 (0.64) NPC1RAB9APKMKMT2ATP53
SCHEMBL22997125 0.79 NPC1 (0.61) NPC1RAB9APKMKMT2ATP53
SCHEMBL16865781 0.77 NPC1 (0.61) NPC1RAB9APKMKMT2ATP53
SCHEMBL28283576 0.76 NPC1 (0.59) NPC1RAB9APKMKMT2ATP53
SCHEMBL28636069 0.76 NPC1 (0.59) NPC1RAB9APKMKMT2ATP53
SCHEMBL28360818 0.76 KMT2A (0.59) NPC1RAB9APKMKMT2ATP53
SCHEMBL2739315 0.75 NPC1 (0.72) NPC1RAB9APKMKMT2ATP53
SCHEMBL23424660 0.75 NPC1 (0.54) NPC1RAB9APKMKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210155604-A1 QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2021-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155604-A1 QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF EGFR, ERBB2, ERBB4 NPC1 1532/4885RAB9A 140/4885PKM 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.